TREATMENT EDUCATION LIBRARY

Cancer Treatment Explained / Immunotherapy

Immunotherapy — A Complete Patient Guide

How treatment works. Who may benefit. Symptoms you should never ignore.

A reference for patients and families, with a focus on immune checkpoint inhibitors. Use the contents to find a topic, or start with the safety advice below.

Medical Content & Review

Dr Hakeem Ansar Hussain

Medical Oncologist

Last medically reviewed:

IMPORTANT SAFETY INFORMATION

When to seek urgent help

Emergency assessment now

Chest pain, severe breathlessness, collapse, confusion, seizures, rapidly progressive weakness, difficulty swallowing or breathing, or other severe symptoms need immediate emergency care. Do not drive yourself if seriously unwell.

Contact your oncology team urgently

Report persistent or worsening diarrhoea, new cough or breathlessness, severe fatigue with dizziness, significant abdominal pain, jaundice, severe headache, new weakness, excessive thirst or frequent urination, and a worsening rash. New symptoms should not wait until your next infusion. If the team cannot be reached promptly, seek urgent medical assessment.

Tell emergency clinicians that you are receiving—or have previously received—immune checkpoint inhibitors. Side effects can begin after treatment stops. Keep the medicine name, last dose date and emergency contact details with you.

In this guide

  1. What is cancer immunotherapy?
  2. How does the immune system recognise cancer?
  3. PD-1, PD-L1 and CTLA-4: checkpoint inhibitors explained
  4. Examples of checkpoint inhibitor medicines
  5. Which cancers may benefit?
  6. Who may be a good candidate?
  7. Immunotherapy biomarkers: what tests can and cannot tell you
  8. Immunotherapy versus chemotherapy
  9. Why combine immunotherapy with chemotherapy?
  10. Before surgery, after surgery and maintenance
  11. How is immunotherapy given?
  12. Before the first treatment: your checklist
  13. What happens on immunotherapy day?
  14. Side effects: mild symptoms and immune-related inflammation
  15. Immune-related colitis: new diarrhoea needs attention
  16. Immune-related pneumonitis: cough or breathlessness
  17. Thyroid and other endocrine complications
  18. Hepatitis and kidney injury: why blood tests matter
  19. Rare but serious: heart, muscle, nerve and skin emergencies
  20. How are immune-related side effects treated?
  21. Can side effects occur after treatment stops?
  22. How do doctors know treatment is working?
  23. What is pseudoprogression?
  24. Why does immunotherapy not work for everyone?
  25. How long is immunotherapy continued?
  26. Immunotherapy and autoimmune disease
  27. Immunotherapy after organ transplantation
  28. Immunotherapy in older patients
  29. Pregnancy, fertility and breastfeeding
  30. Diet, exercise, work and daily life
  31. Immunotherapy myths versus facts
  32. Frequently asked questions
  33. Questions to ask your oncologist
  34. Other forms of cancer immunotherapy
  35. Keep your emergency plan close
  36. A final message for patients and families
  37. Sources & Medical Review

What is cancer immunotherapy?

Cancer immunotherapy is a family of treatments that helps the immune system recognise or attack cancer. The immune system includes white blood cells, tissues and organs that defend us against infection and respond to abnormal cells. Cancer develops from our own cells and can hide from, suppress or resist those defences.

This guide focuses mainly on immune checkpoint inhibitors. They change signals that regulate immune responses. Other immunotherapies work differently: some supply specially prepared immune cells, while others help immune cells find a target. There is no single “immunotherapy medicine.”

Unlike cytotoxic chemotherapy, checkpoint inhibitors do not primarily work by directly damaging dividing cells. They help an immune response act against a susceptible cancer. That difference explains both their potential benefits and their distinctive side effects.

Immunotherapy may contribute to curative-intent treatment in some settings, or aim to control cancer, relieve symptoms and prolong life when cure is not expected. A treatment goal is not a promise. Some patients experience long-lasting responses, occasionally continuing after treatment ends, possibly because immune activity and memory persist. Many cancers do not respond, and a response can eventually be lost.

How does the immune system recognise cancer?

T lymphocytes (T cells)
These white blood cells help coordinate immune responses; some can kill abnormal cells after recognising a suitable target.
Antigens and recognition
Antigens are molecular features the immune system can recognise. Cells display small protein fragments on their surface. Changes in cancer cells can create unfamiliar fragments, but not every tumour displays an easily recognised target.
Immune activation
Recognition alone may not be enough. T cells need additional activating signals and a supportive environment to multiply, reach the tumour and function.
Immune checkpoints
These normal control pathways limit excessive responses and help protect healthy tissues. Cancer can exploit them to weaken an immune attack.
Immune escape
A cancer may stop displaying recognisable antigens, increase suppressive signals or exclude immune cells. Several escape mechanisms may operate together.
The tumour microenvironment
This is the neighbourhood around a tumour: immune cells, blood vessels, supporting tissue and chemical signals. It may support an immune attack or prevent one.

Think of checkpoints as brakes on immune activity. Releasing a brake can help an existing response, but it does not guarantee that immune cells can identify or reach the cancer. The analogy also leaves out the many interacting signals involved—and the risk of inflammation in healthy organs.

PD-1, PD-L1 and CTLA-4: checkpoint inhibitors explained

PD-1 inhibitors

PD-1 is a receptor on T cells. When it binds to partners such as PD-L1, it can reduce T-cell activity. Blocking PD-1 can interrupt this inhibitory signal and help restore activity against certain cancers. It cannot overcome every cause of immune escape.

PD-L1 inhibitors

PD-L1 can be present on cancer cells and on immune or other healthy cells. Blocking it interrupts an immune-suppressive interaction with PD-1. PD-1 and PD-L1 medicines affect related pathways but have different licensed uses and evidence; they are not automatically substitutes.

CTLA-4 inhibitors

CTLA-4 is another checkpoint, involved particularly in regulating early T-cell activation. Blocking it can broaden or strengthen immune responses. Its biology overlaps with other pathways but is not identical to PD-1 blockade.

Why combine checkpoint inhibitors?

Blocking complementary checkpoints can improve outcomes in selected cancers. Some regimens combine PD-1 and CTLA-4 blockade; another approach combines PD-1 and LAG-3 blockade. More immune activation can also mean more toxicity. Each combination needs evidence for the specific cancer and clinical setting; “two is better than one” is not a general rule.

Examples of checkpoint inhibitor medicines

This is an illustrative list, not a prescribing list. Approval, formulation, age eligibility, combinations and availability vary by country and change over time. Your team should check the current local prescribing information.

Examples grouped by the checkpoint they block
CheckpointExamples
PD-1Pembrolizumab, nivolumab, cemiplimab, dostarlimab
PD-L1Atezolizumab, durvalumab, avelumab
CTLA-4Ipilimumab, tremelimumab
LAG-3Relatlimab, used in an approved combination with nivolumab in selected settings

Other agents are approved in particular countries. A medicine listed here is not necessarily approved for each cancer below. Drugs, doses and formulations must not be exchanged without the treating team’s direction.

Which cancers may benefit?

Checkpoint inhibitors have established roles in selected patients with the cancers below. For every row, eligibility depends on stage, biomarkers where relevant, previous treatment, clinical condition and the exact regimen. This overview is not an exhaustive list of indications.

Cancer type and key treatment considerations
CancerWhy the details matter
Lung cancerOptions differ between small-cell and non-small-cell disease. Stage, PD-L1 and molecular drivers help determine the role of immunotherapy, chemotherapy, targeted treatment and treatment around surgery or radiotherapy.
MelanomaCheckpoint blockade may be used around surgery or in advanced disease. Recurrence risk, resectability, symptoms and the balance between single-agent and combination toxicity matter.
Kidney cancerSelected advanced cancers receive checkpoint combinations or immunotherapy with targeted drugs. Some higher-risk patients have an adjuvant option after surgery; histology and recurrence risk matter.
Bladder and urothelial cancerRoles include selected perioperative, advanced-disease and maintenance settings. Prior platinum therapy, response, surgical plan and the proposed partner medicine influence choice.
Head and neck cancerCheckpoint inhibitors have roles in selected recurrent/metastatic disease and specific perioperative settings. Histology, PD-L1, prior treatment and local approvals influence the plan.
Colorectal cancerMSI-H/dMMR cancers are substantially more sensitive to checkpoint blockade than most microsatellite-stable (MSS) cancers. Immunotherapy is not routine for most MSS colorectal cancers. Stage and molecular findings determine whether an established approach or a clinical trial is relevant.
Gastric and gastro-oesophageal cancersHistology, stage, PD-L1, MSI/MMR and other biomarkers can affect treatment. The role of immunotherapy and its partner treatment varies across oesophageal, junctional and stomach cancers.
Breast cancerThe clearest routine checkpoint roles are in selected triple-negative disease. High-risk early and metastatic settings have different biomarker requirements. It is not standard for every breast cancer subtype.
Liver cancerSelected hepatocellular cancers may receive immunotherapy combinations. Liver reserve, bleeding risk, viral hepatitis and transplant history can strongly affect suitability.
Endometrial cancerMMR status is important. Some combinations have roles beyond dMMR disease, but stage, previous therapy and the exact regimen determine eligibility.
Cervical cancerRoles exist in defined locally advanced or recurrent/metastatic settings, sometimes with chemoradiotherapy or chemotherapy. PD-L1 requirements depend on the indication.
Classical Hodgkin lymphomaPD-1 blockade may form part of selected initial or relapse regimens. Previous therapy and any stem-cell transplantation plan require specialist coordination.
Selected other cancersExamples include certain skin, biliary tract and other cancers. Tumour-agnostic approvals based on biomarkers apply only within their specified conditions. In prostate cancer, checkpoint inhibitors are relevant mainly to selected molecular subsets, not most patients.

Immunotherapy can be given before or after surgery, with or after chemoradiotherapy, in advanced disease or as maintenance when supported for that indication. These settings are not interchangeable.

Who may be a good candidate?

Your oncologist combines information about the tumour with information about you. No single test or characteristic decides eligibility for every cancer.

  • Cancer type, stage and goal: whether benefit has been shown for this situation and whether treatment aims to cure or control disease.
  • Biomarkers and previous treatment: which tests change the choice and what has already been tried.
  • Performance status: how illness affects everyday activity, and whether impairment is potentially reversible.
  • Autoimmune disease or organ transplantation: the risk of a flare, organ injury or rejection.
  • Organ function and medical history: existing lung, heart, kidney, liver and endocrine problems, infections and other conditions.
  • Practical priorities: access, affordability, travel, monitoring, support and personal preferences.

Ask about the expected absolute benefit, meaningful alternatives and treatment burden. An expensive or newer treatment is not automatically the right treatment.

Immunotherapy biomarkers: what tests can and cannot tell you

PD-L1 expression

A laboratory usually stains tumour tissue to measure PD-L1 protein. Different tests count different cells. A tumour proportion score (TPS) measures the percentage of viable tumour cells staining for PD-L1. A combined positive score (CPS) also includes certain PD-L1-staining immune cells in relation to the number of viable tumour cells. Other scoring methods exist.

Assay, sample quality, tumour type and treatment setting affect interpretation. PD-L1 can vary within a tumour and over time. A score from one method cannot simply be substituted for another. A positive result does not guarantee benefit, and a negative result does not universally exclude immunotherapy. Some regimens require a defined result; others do not.

MSI-H and dMMR

Mismatch repair is a system that corrects errors when DNA is copied. Deficient mismatch repair (dMMR) means this repair system is not working normally. Errors can accumulate in repeated DNA sequences, producing high microsatellite instability (MSI-H). These related findings can be assessed with protein staining or molecular tests; occasionally results need clarification.

Such cancers may generate abnormal proteins that make them easier for immune cells to recognise. MSI-H/dMMR can predict checkpoint sensitivity in several tumour types, but it does not guarantee a response. It can sometimes raise the possibility of an inherited condition such as Lynch syndrome; a tumour result alone does not diagnose an inherited syndrome.

Tumour mutational burden (TMB)

TMB estimates how many mutations are present in the DNA examined, often reported per megabase. A higher number can increase opportunities for immune recognition, but not all mutations produce useful immune targets. Results depend on the test, tissue versus blood sampling, cutoff and tumour biology.

TMB has a role in selected regulatory indications; it is not a universal substitute for PD-L1 or MSI/MMR, and a “high” result is not equally predictive across all cancers. Your team must interpret the actual assay and applicable evidence.

Other tumour-specific factors

Molecular drivers may favour targeted treatment instead. For example, certain driver-positive lung cancers require a different sequence even with a high PD-L1 score. Immune-cell access to the tumour and other biological features also matter, although many proposed immune tests remain investigational.

Read Cancer Biomarkers & Precision Oncology for help understanding tissue tests, molecular reports and their limitations.

Immunotherapy versus chemotherapy

Different tools, chosen for different reasons
QuestionCheckpoint immunotherapyCytotoxic chemotherapy
Main actionChanges immune-regulating signals to support an anticancer response.Directly damages cancer cells or interferes with cell division.
Response patternMay cause shrinkage or stable disease; some responses last a long time. Many cancers resist it.Shrinkage or control depends on the cancer and regimen; chemotherapy can also cure some cancers.
Characteristic risksInflammation of healthy organs, sometimes delayed or persistent; infusion reactions can occur.Depending on the drug: low blood counts, nausea, mouth sores, hair loss, nerve injury and other organ effects.
MonitoringSymptoms, relevant blood tests and scans, including checks for immune toxicity.Symptoms, blood counts, organ function and scans, tailored to the regimen.

Neither treatment is universally better. Evidence in the same cancer and setting—not survival figures from unrelated cancers—guides the choice. Some patients benefit most from a combination. See the Chemotherapy — Complete Patient Guide for detailed preparation and safety advice.

Why combine immunotherapy with chemotherapy?

Chemotherapy can reduce tumour burden and may alter the release of tumour antigens and the immune environment. Checkpoint blockade acts on immune regulation. In some cancers, trials show that combining them improves outcomes compared with the relevant alternative.

This biological explanation is not proof that every combination works. The benefit must justify added treatment burden. Fatigue, diarrhoea, lung symptoms or abnormal blood tests may have several possible causes when treatments overlap; the team must distinguish immune inflammation from infection, chemotherapy toxicity and cancer.

Schedules differ by regimen. Some plans begin with both and continue immunotherapy alone after a planned chemotherapy course. This is a planned treatment phase, not necessarily a sign that chemotherapy stopped working. Other patients are better served by one approach or a different combination.

Before surgery, after surgery and maintenance

Neoadjuvant
Given before surgery, often to treat microscopic disease early and improve tumour control. The surgical timetable remains part of a coordinated plan.
Perioperative
A planned course spanning treatment before and after surgery. Eligibility and postoperative treatment depend on the specific protocol and recovery.
Adjuvant
Given after surgery to reduce recurrence risk from cells that may remain but cannot be seen. Benefit is judged against recurrence risk and potential lasting toxicity.
Maintenance
Continued treatment after an initial phase to sustain cancer control. Not every regimen uses this approach.

After chemoradiotherapy, selected patients may receive consolidation immunotherapy. It is not the same as giving all treatments together. Every approach is cancer-specific, with its own evidence, timing and safety requirements.

How is immunotherapy given?

Most checkpoint inhibitors are given by intravenous infusion in an oncology day-care unit or infusion centre. Selected subcutaneous formulations—an injection under the skin—are approved in some countries and settings. They have their own instructions and cannot be assumed suitable for every use of an intravenous medicine.

Visits may be separated by a few weeks, but the interval, infusion time, observation period and total duration depend on the medicine, formulation and indication. Combination drugs may be administered on different schedules. Treatment is prescribed and verified by trained professionals.

Immunotherapy alone does not necessarily need the same anti-sickness medicines, steroids or growth-factor injections as chemotherapy. Some medicines require premedication for infusion reactions, and combination treatment may require chemotherapy premedication. Follow your own prescription; do not omit prescribed steroids because you have heard they “cancel” immunotherapy.

Before the first treatment: your checklist

Assessment is personalised. Not every patient needs every test below.

  • Confirm the diagnosis, stage, treatment goal, medicine names, expected benefit and alternatives.
  • Review the biomarkers that matter for your cancer and whether results are complete.
  • Tell the team about autoimmune disease, previous immune toxicity, organ transplantation or stem-cell transplantation.
  • Report past lung, heart, liver, kidney, thyroid, adrenal or pituitary problems, diabetes and relevant infections.
  • Complete prescribed baseline blood tests, typically including blood counts, liver and kidney function, electrolytes, glucose and thyroid tests. Other endocrine, heart, lung or infection assessments depend on risk and regimen.
  • Bring all medicines, allergies, vitamins, herbal products and supplement details. Mention steroid tablets, injections and other immune-suppressing medicines.
  • Discuss pregnancy testing, contraception, fertility concerns and breastfeeding before treatment.
  • Record your usual bowel pattern, energy level and any existing cough, rash or joint symptoms to make new changes easier to identify.
  • Discuss immune-related side effects and obtain a treatment alert card or written medicine list.
  • Save the oncology contact number, an out-of-hours number and instructions for emergency assessment. Ask what to do if no one answers.

What happens on immunotherapy day?

  1. Symptom review: report changes since the last visit, even if mild or apparently unrelated.
  2. Delayed-toxicity assessment: tell staff about diarrhoea, cough, weakness, rash, headaches, thirst or symptoms after earlier doses.
  3. Relevant tests: the team reviews required laboratory results and any additional assessments.
  4. Eligibility decision: treatment may proceed, be delayed or require further investigation.
  5. Preparation and verification: staff check your identity, medicine, formulation and treatment plan.
  6. Administration: receive the infusion or approved injection with appropriate observation.
  7. Reaction monitoring: immediately report flushing, itching, chills, chest or back discomfort, dizziness, wheezing or breathing difficulty.
  8. Discharge advice: confirm prescribed medicines, warning signs and contact details.
  9. Follow-up: confirm blood tests, scans and the next visit.

Feeling well during the infusion does not rule out a later immune complication. Symptoms between visits need attention; do not wait for your next treatment appointment.

Side effects: mild symptoms and immune-related inflammation

Checkpoint inhibitors can alter immune activity against healthy tissue as well as cancer. This may cause an immune-related adverse event: inflammation affecting almost any organ. Many effects are manageable when recognised early. Severe events are less common but can be life-threatening or leave lasting problems.

A mild symptom does not always mean a dangerous complication, but symptoms cannot reliably identify the cause at home. Infection, other medicines and cancer itself can cause similar problems. Report changes promptly so your team can assess them.

Fatigue

Mild tiredness is common. Report worsening fatigue, especially with dizziness, breathlessness, headache, weakness, thirst or reduced ability to function. These combinations may point to anaemia, endocrine problems, heart or lung complications, or other causes needing assessment.

Skin rash and itching

Tell the team about a new or spreading rash. They may recommend moisturisers, a topical treatment or other medicines after assessment. Blistering, peeling, painful skin, mouth or eye sores, or a rash with fever needs urgent assessment. Do not assume every rash is a harmless allergy.

Joints and muscles

Inflammatory arthritis can cause painful, stiff or swollen joints and may persist after treatment. Report symptoms early. New true muscle weakness—difficulty standing, lifting your arms, swallowing or holding your head up—is different from ordinary tiredness and may require emergency assessment.

Other organs

Colitis, pneumonitis, hepatitis, nephritis, hormone deficiencies, myocarditis, myositis and neurological inflammation are described below. Less common problems can involve the eyes, blood cells or other tissues. New visual changes or unusual bleeding also need prompt assessment.

You do not need to develop side effects for treatment to work. Absence of toxicity is not evidence of treatment failure.

Immune-related colitis: new diarrhoea needs attention

Colitis means inflammation of the colon. Symptoms may include looser or more frequent stools, urgency, abdominal cramps, mucus or blood in stool and diarrhoea at night. Persistent diarrhoea can cause dehydration and electrolyte problems; severe inflammation can damage the bowel.

Contact your oncology team promptly for new or worsening diarrhoea. Record how many stools you have compared with your usual pattern, whether there is blood, and any pain or fever. Significant abdominal pain, blood in the stool, inability to drink, faintness or rapid deterioration warrants urgent assessment.

Infection and other treatments can also cause diarrhoea. Assessment may include blood and stool tests, imaging or endoscopy when indicated. Do not self-start steroids or use antidiarrhoeal medicines as a substitute for assessment; ask the team what is safe in your situation. Keep drinking fluids if able while arranging care, but do not delay care to try home remedies.

Immune-related pneumonitis: cough or breathlessness

Pneumonitis is inflammation of lung tissue. It can cause a new dry cough, breathlessness, chest discomfort, fever or reduced oxygen levels. Occasionally it is first detected on a scan.

These symptoms can resemble pneumonia, a blood clot, heart problems or cancer-related changes. Clinical assessment—often including oxygen measurement, chest imaging and tests for infection—is needed to identify the cause.

New or worsening breathlessness is potentially serious. Contact oncology urgently for new respiratory symptoms. Severe breathlessness, difficulty speaking because of breathing, blue lips, chest pain or rapid worsening needs emergency care. Do not wait for an oxygen reading or assume a normal home reading makes symptoms safe.

Thyroid and other endocrine complications

Endocrine glands make hormones that regulate energy, blood pressure, metabolism and other functions. Immune inflammation can disrupt these glands. Symptoms may be vague, which is why laboratory monitoring matters.

Thyroiditis, hyperthyroidism and hypothyroidism

Inflammation can release stored thyroid hormone, causing a temporary overactive phase with palpitations, sweating, tremor or weight loss. This may be followed by an underactive thyroid, causing tiredness, cold intolerance, constipation or weight gain. Other patterns occur. Thyroid blood tests guide treatment; some people need long-term hormone replacement.

Hypophysitis

Inflammation of the pituitary gland can disrupt several hormones, including signals that tell the adrenal glands to make cortisol. Headache, marked fatigue, nausea, dizziness or visual changes require assessment. A severe new headache or neurological symptoms need urgent care.

Adrenal insufficiency

Too little cortisol can result from pituitary or adrenal injury. Severe weakness, dizziness on standing, vomiting, abdominal pain, low blood pressure, confusion or collapse may signal an adrenal crisis. Severe symptoms require emergency assessment. If diagnosed, obtain written instructions for illness, missed medicines and emergency hormone treatment; never abruptly stop prescribed replacement.

Insulin-deficient diabetes and ketoacidosis

Rarely, checkpoint therapy damages insulin-producing cells and diabetes develops rapidly. New excessive thirst, frequent urination or unexplained weight loss needs urgent testing. Vomiting, abdominal pain, deep or rapid breathing, drowsiness or confusion may indicate diabetic ketoacidosis and require emergency care. It can occur in someone with no previous diabetes.

Some endocrine damage is permanent even after immunotherapy stops. Treatment often replaces the missing hormone; high-dose immune suppression is not automatically helpful for every endocrine problem. More than one gland can be affected, so doctors coordinate the order and type of replacement.

Hepatitis and kidney injury: why blood tests matter

Immune-related hepatitis

Liver inflammation may initially cause no symptoms and appear only as abnormal liver blood tests. Jaundice, dark urine, significant nausea or right-sided upper abdominal pain needs urgent medical advice. Medicines, infection, blocked bile ducts and cancer can also affect liver tests, so the cause must be investigated.

Nephritis and other kidney problems

Inflammation of the kidneys may be detected through a rise in creatinine before you feel unwell. Urine tests may help. Dehydration, infection, obstruction and other medicines can also injure the kidneys.

Markedly reduced urine output, jaundice or significant clinical deterioration needs urgent assessment. Keep scheduled blood tests even when you feel well. Do not try to correct an abnormal result by stopping prescribed medicines or taking herbal “cleanses” yourself.

Rare but serious: heart, muscle, nerve and skin emergencies

Act immediately for severe or rapidly developing symptoms

Chest pain, palpitations with faintness, collapse, severe breathlessness, rapidly progressive weakness, difficulty swallowing or breathing, confusion or seizures require emergency assessment.

Myocarditis

Inflammation of heart muscle can affect pumping and electrical rhythm. Symptoms may include chest discomfort, breathlessness, palpitations, fainting or unusual fatigue. It can deteriorate quickly and needs urgent specialist evaluation.

Myositis and myasthenia-like syndromes

Muscle inflammation or disruption of nerve-to-muscle signalling can cause new weakness, drooping eyelids, double vision, difficulty holding up the head, swallowing problems or breathing weakness. Heart, muscle and nerve-to-muscle complications can overlap. New drooping eyelids or muscle weakness needs urgent assessment even before breathing is affected.

Neurological inflammation

Inflammation may affect the brain, spinal cord or nerves. New confusion, seizures, weakness, walking difficulty, severe headache or sensory changes requires prompt assessment; severe or rapidly progressive symptoms are emergencies.

Severe skin and endocrine reactions

Blistering or peeling skin and painful mouth or eye lesions may indicate a serious skin reaction. Adrenal crisis and diabetic ketoacidosis are endocrine emergencies. Seek care immediately for severe symptoms rather than waiting to identify a specific diagnosis.

How are immune-related side effects treated?

The team first assesses the organ involved and severity, while looking for other causes such as infection, cancer progression or another medicine. Investigations may involve blood tests, imaging and specialist review; selected cases need a biopsy or procedure.

  • Mild events: some can be managed with local or supportive treatment and close monitoring.
  • Withholding treatment: immunotherapy may be paused while the problem is assessed and treated.
  • Corticosteroids: used for selected inflammatory toxicities under medical supervision. The dose and taper depend on the problem; never start, change or abruptly stop them yourself.
  • Additional immune suppression: organ-specific treatment may be needed when steroids are insufficient or unsuitable.
  • Hospital care: serious events may require admission, intensive monitoring and several specialists.
  • Hormone replacement: thyroid hormone, cortisol replacement or insulin may be needed, sometimes permanently.

High-dose steroids can increase infection risk and affect glucose, sleep and other systems. Monitoring and preventive medicines may be prescribed. Treating a dangerous toxicity is essential; do not avoid necessary treatment out of fear that it will automatically erase the anticancer benefit.

Restarting checkpoint therapy depends on recovery, the organ involved, severity, expected cancer benefit and alternatives. Some serious events require permanent discontinuation. These are individual medical decisions, not choices to make from a checklist at home.

Can side effects occur after treatment stops?

Yes. Immune-related events can begin during treatment or weeks or months after the last dose. Some persist much longer, and there is no universal date after which new symptoms can safely be dismissed as unrelated.

Keep your medicine names, last treatment date and history of immune complications available. Tell emergency staff, your family doctor and other specialists that you have received checkpoint inhibitors, even after the course has finished. Continue the follow-up and hormone monitoring recommended by your team.

How do doctors know treatment is working?

Assessment brings together how you feel, examination findings, laboratory results and imaging. CT or MRI is commonly used; PET-CT is useful in selected settings, not automatically for every cancer or visit. Inflammation can also cause PET activity.

Complete response
No detectable cancer by the assessment method used. It does not always mean cure or exclude microscopic disease.
Partial response
A defined reduction in measurable cancer, without meeting complete-response criteria.
Stable disease
Neither enough shrinkage for a partial response nor enough growth for progression. This can represent useful control.
Progression
Growth, new disease or other evidence that cancer is worsening, interpreted in the full clinical context.

Scan timing depends on the cancer and treatment plan. A symptom change or one laboratory result alone cannot reliably prove success or failure. In adjuvant treatment there may be no visible tumour to measure; the aim is to lower future recurrence risk.

What is pseudoprogression?

Occasionally a tumour looks larger, or new lesions appear, before later improvement. Immune-cell infiltration, inflammation and changes within the tumour may contribute. This pattern is called pseudoprogression.

Pseudoprogression is uncommon in most solid tumours. Apparent progression is more often genuine progression. It must not become a reason to ignore worsening symptoms or repeatedly continue an ineffective medicine.

If a patient is clinically stable and the situation allows it, the oncologist may arrange repeat imaging or another assessment to clarify an uncertain scan. Research criteria such as iRECIST describe confirmatory assessment, but they are not instructions for patients to continue treatment independently. Clinical deterioration may require urgent investigation and a change of treatment without waiting.

Hyperprogression refers to a reported pattern of unusually rapid tumour growth after treatment begins. Its definitions, causes and relationship to immunotherapy remain debated. It is different from pseudoprogression; a worsening patient needs assessment regardless of the label.

Why does immunotherapy not work for everyone?

Some tumours are poorly recognised by immune cells, fail to display useful antigens, keep T cells out or create a strongly suppressive microenvironment. Releasing a checkpoint cannot fix every barrier. Biomarkers estimate the likelihood of benefit but do not fully describe this biology.

Primary resistance means there is no meaningful benefit from the start. Acquired resistance means cancer begins growing after an initial response or period of control, for example as resistant cell populations emerge or immune recognition changes.

Treatment failure is not the patient’s fault. Positive thinking, special diets and “immune-boosting” supplements have not been shown to overcome checkpoint resistance. Depending on the situation, options may include another established treatment, a clinical trial or a greater focus on symptom relief and quality of life.

How long is immunotherapy continued?

Duration depends on cancer type, stage, treatment intent, regimen, response, toxicity and the clinical-trial evidence supporting the plan. Some curative-intent or perioperative courses have a defined endpoint. Some advanced-disease regimens continue until progression, unacceptable toxicity or a protocol-defined limit.

Not everyone needs two years of treatment. A duration used in one trial does not apply to all medicines or cancers. Completing a planned course, stopping for toxicity and stopping for progression are different situations.

Ask what endpoint is planned, when it will be reconsidered, what follow-up is needed and whether restarting later is supported for your specific setting. Continuing indefinitely may add risk and cost without established additional benefit.

Immunotherapy and autoimmune disease

Pre-existing autoimmune conditions may flare when immune checkpoints are blocked, and new immune-related problems may develop. Risk varies with the condition, organs affected, current activity and medicines needed to control it.

Autoimmune disease is not always an absolute contraindication. The oncology team may work with a rheumatologist, gastroenterologist, neurologist or another specialist to weigh likely cancer benefit against flare risk and plan monitoring. Severe or poorly controlled disease may substantially change the recommendation.

Do not stop autoimmune medicines on your own. The team must balance disease control, treatment safety and cancer outcomes.

Immunotherapy after organ transplantation

Checkpoint blockade can trigger rejection of a transplanted kidney, liver, heart, lung or other organ. Rejection can be irreversible and may lead to organ failure or death. Maintaining anti-rejection medicines does not guarantee protection.

This requires a specialist multidisciplinary discussion involving oncology and the transplant team, with careful consideration of alternatives and the consequences of graft loss. General reassurance is inappropriate. A history of allogeneic stem-cell transplantation also needs separate specialist review because checkpoint therapy can affect graft-versus-host disease risk.

Immunotherapy in older patients

Chronological age alone does not determine suitability. Functional ability, frailty, cognition, nutrition, organ function, other conditions and available support are often more useful than a birthday.

An older adult who remains active may tolerate treatment differently from someone of the same age with multiple medical problems. Assessment should include the chance of meaningful benefit, potential hospital visits, recovery from toxicity and the person’s priorities. Immune therapy is not automatically gentle simply because it is not chemotherapy.

Pregnancy, fertility and breastfeeding

Checkpoint pathways help regulate immune tolerance during pregnancy. These medicines may harm a developing baby, so pregnancy or plans for pregnancy must be discussed before treatment. If pregnancy is suspected during therapy, contact the treating team promptly.

Use medicine-specific advice about effective contraception during and after treatment. There is no single safe interval that applies to every checkpoint inhibitor or partner medicine. Breastfeeding generally needs to be avoided during treatment and for the period specified for that medicine; ask for the exact instructions.

The direct effects of checkpoint inhibitors on fertility are not fully defined. Endocrine injury and accompanying chemotherapy can affect reproductive health. Discuss fertility preservation before treatment when relevant and feasible, and ask about sexual symptoms or menstrual changes rather than assuming they are unavoidable.

Diet, exercise, work and daily life

Food and hydration

Most people can eat a normal balanced diet as tolerated. Choose adequate calories and protein, safe food handling and regular fluids, unless you have a prescribed fluid restriction. Seek dietitian support for weight loss or poor intake. Diarrhoea, nausea or endocrine problems may require specific advice after assessment.

Physical activity and work

Gentle regular activity, adjusted to energy and physical ability, can help maintain function. Stop and seek advice for new breathlessness, chest pain, dizziness or weakness. Work may be possible, but flexible hours and rest may help. Do not push through warning symptoms.

Travel

Discuss timing around appointments, blood tests and access to urgent care. Carry your treatment card, medicine list, contact numbers and insurance information. Delayed toxicity is possible even when a trip falls between doses or after treatment has ended.

Infections and vaccinations

Checkpoint therapy alone does not usually produce the same predictable bone marrow suppression as cytotoxic chemotherapy. Infection risk changes with chemotherapy, immune-suppressing treatment for toxicity and other conditions. Fever still requires advice; follow your team’s fever plan, particularly during combination treatment.

Discuss recommended vaccines and timing with oncology. Live vaccines need particular consideration if you are immunosuppressed. Do not assume all vaccines are forbidden or that every vaccine is appropriate at any time.

Supplements and herbal products

There is no proven supplement that makes checkpoint therapy work. Products marketed as “immune boosters” can cause toxicity or interfere with care. Tell the team what you take, including non-prescription products; do not replace treatment with a supplement.

Immunotherapy myths versus facts

Myth: Immunotherapy works for every cancer.

Fact: Only selected cancers and clinical settings have proven benefit; even eligible patients may not respond.

Myth: Immunotherapy has no serious side effects.

Fact: Immune inflammation can affect healthy organs, occasionally causing life-threatening or permanent problems.

Myth: It is always better than chemotherapy.

Fact: The best choice depends on evidence for your cancer. Sometimes chemotherapy or a combination is preferred.

Myth: A positive PD-L1 test guarantees success.

Fact: It may help guide selection, but cannot guarantee a response.

Myth: Negative PD-L1 means it never works.

Fact: Some effective regimens do not require PD-L1 positivity.

Myth: It always cures advanced cancer.

Fact: Some patients have durable control, but cure is not a general expectation or promise.

Myth: It causes the same hair loss as chemotherapy.

Fact: Typical widespread chemotherapy-related hair loss is less usual with checkpoint therapy alone. Immune-related hair changes can occur, and a chemotherapy partner may cause hair loss.

Myth: Side effects stop as soon as treatment ends.

Fact: Some continue or begin after the last dose; ongoing awareness and monitoring matter.

Myth: A worse scan must be pseudoprogression.

Fact: True progression is more common. The oncology team must assess the scan and clinical picture.

Myth: Regular monitoring is optional.

Fact: Some organ inflammation starts silently. Keep scheduled reviews and blood tests.

Myth: All immunotherapy medicines are interchangeable.

Fact: They differ in targets, evidence, indications, formulations and risks.

Frequently asked questions

What is immunotherapy?

A group of treatments that helps the immune system act against cancer. This guide mainly covers immune checkpoint inhibitors.

Is immunotherapy chemotherapy?

Checkpoint inhibitors work through immune regulation rather than primarily damaging dividing cells. They can be given with chemotherapy.

Can immunotherapy cure cancer?

It can contribute to curative treatment in selected situations. In advanced cancer, some responses are durable, but a cure cannot be assumed.

Does it work for everyone?

No. Eligibility and the chance of benefit depend on tumour biology, clinical setting and other factors.

How is it given?

Usually by infusion; selected subcutaneous formulations are available for specific approved uses.

How long does treatment last?

The plan may have a fixed endpoint or depend on response and toxicity. Two years is not a universal rule.

Is immunotherapy painful?

A cannula or injection may briefly sting. Infusion itself is not expected to be painful; report pain, swelling or any sudden symptom to the nurse.

Does it cause hair loss?

Typical chemotherapy-like hair loss is less common with checkpoint therapy alone, but immune-related hair loss and effects of combination chemotherapy are possible.

What is PD-L1?

A protein involved in suppressing immune activity. Tissue testing can guide certain regimens, but a result is not a guarantee of benefit.

What is MSI-H?

High microsatellite instability: a pattern of DNA errors often linked to deficient mismatch repair. It can help identify cancers sensitive to checkpoint therapy.

Can it be combined with chemotherapy?

Yes, where trials support a specific combination. Combining treatments is not automatically right for everyone.

What are the serious side effects?

Inflammation can affect bowel, lungs, liver, kidneys, endocrine glands, heart, muscles, nerves and skin. Severe or rapidly worsening symptoms need urgent care.

Can side effects occur after stopping?

Yes, including weeks or months later. Tell clinicians about previous checkpoint therapy.

What is pseudoprogression?

An uncommon pattern of apparent initial worsening followed by improvement. Most apparent progression is real, so reassessment must be directed by oncology.

How is response assessed?

With symptoms, examination, relevant blood tests and scans such as CT or MRI; PET-CT is used in selected settings.

Can patients with autoimmune diseases receive it?

Sometimes. The type and activity of disease, medicines and cancer benefit require individual specialist assessment.

What should I tell an emergency doctor?

Say that you are receiving—or previously received—an immune checkpoint inhibitor. Give its name, last dose date, any prior immune toxicity and current medicines, especially steroids or hormone replacement.

Questions to ask your oncologist

  • Why is immunotherapy recommended for my cancer?
  • What is the goal of treatment?
  • Which biomarkers matter, and are the results complete?
  • Will I receive it alone or with other medicines?
  • How often will treatment be given?
  • What benefit is realistically expected, and what are the alternatives?
  • Which symptoms need urgent attention?
  • How will response be assessed?
  • How long is treatment planned?
  • What happens if it does not work?
  • What happens if an immune-related side effect develops?
  • Whom should I contact outside clinic hours?

Other forms of cancer immunotherapy

Checkpoint inhibitors are one part of a broader field. These technologies have different mechanisms, indications and safety needs:

CAR-T cell therapy
A patient’s T cells are collected and engineered to recognise a cancer target, then returned after specialised preparation. Established uses are mainly in selected blood cancers. Cytokine release syndrome, neurological toxicity, infection and prolonged low blood counts need specialist monitoring.
Bispecific T-cell-engaging antibodies
These can bind a tumour target and a T-cell target, bringing the cells together. Selected products are established treatments; others are investigational. Step-up administration and monitoring may be needed for cytokine release syndrome and other risks.
Therapeutic cancer vaccines
These aim to generate an immune response against an existing cancer. A few approaches have established uses; many personalised or other vaccines remain experimental. They are different from HPV and hepatitis B vaccines used to prevent infections that can cause cancer.
Adoptive cellular therapies
Selected or expanded immune cells, such as tumour-infiltrating lymphocytes, are given back to the patient. Certain approaches have approved uses in particular countries; many remain in trials and may require intensive preparation and support.
Selected monoclonal antibody approaches
Some antibodies mark cancer cells for immune destruction; others block growth signals or deliver a cytotoxic payload. Classification can overlap, but not every monoclonal antibody is a checkpoint inhibitor, and not every targeted antibody works primarily through the same immune mechanism.

Other immune approaches include selected cytokine treatments and intravesical BCG for certain bladder cancers. Their risks should not be inferred from a checkpoint inhibitor guide. Ask for education specific to the treatment you are receiving.

Keep your emergency plan close

Do not wait for the next appointment

Contact oncology urgently for new or worsening diarrhoea, cough, breathlessness, severe fatigue with dizziness, abdominal pain, jaundice, severe headache, new weakness, excessive thirst, frequent urination or a worsening rash.

Seek emergency care immediately for chest pain, severe breathlessness, collapse, confusion, seizures, rapidly progressive weakness, difficulty swallowing or breathing, or other severe symptoms. If the team cannot be reached promptly, seek urgent medical assessment.

Tell clinicians: “I am receiving, or have previously received, an immune checkpoint inhibitor.” Carry the drug name, last dose date and oncology contact details.

A final message for patients and families

Immunotherapy has transformed treatment for several cancers, but it is not suitable for every patient and does not work for everyone. The choice depends on cancer type, stage, biomarkers, medical history and the best available evidence.

Recognising immune-related side effects early is essential. Reporting a symptom is a way to protect your health, not an admission that you cannot manage treatment.

Cancer Aware provides educational information and does not replace individual medical advice. Continue with Cancer Treatment Explained, the Chemotherapy Guide, Biomarkers & Precision Oncology or the Cancer Types library. Read our Medical Disclaimer.

Sources & Medical Review

Medical Content & Review

Dr Hakeem Ansar Hussain

Medical Oncologist

Last medically reviewed:

These sources support the explanations of mechanisms, selection, safety and response assessment. Guideline and regulatory information is intended to inform clinical review, not self-treatment. Drug approvals vary by country; an older label is not a complete current list of indications.

  1. National Cancer Institute: Immunotherapy to Treat Cancer
  2. National Cancer Institute: Immune Checkpoint Inhibitors
  3. National Cancer Institute: Immunotherapy Side Effects
  4. American Cancer Society: Immune Checkpoint Inhibitors and Their Side Effects
  5. Cancer Research UK: Checkpoint Inhibitors
  6. Cancer Research UK: Immunotherapy and Its Side Effects
  7. SITC: Immune Checkpoint Inhibitor-related Adverse Events guideline and living updates
  8. ASCO: Management of immune-related adverse events, guideline update (Schneider et al., 2021)
  9. ESMO: Patient Guide on Immunotherapy Side Effects
  10. Brahmer et al. SITC clinical practice guideline, 2021. doi:10.1136/jitc-2021-002435
  11. Seymour et al. iRECIST response criteria for immunotherapy trials, 2017
  12. MedlinePlus: PD-L1 Tests
  13. FDA: Pembrolizumab prescribing information, 2025 label (US reference; check current local label)
  14. FDA: Subcutaneous pembrolizumab formulation approval, September 2025

Source links checked during preparation on 9 October 2026. See the established Sources & Medical Review policy and Medical Disclaimer.

Recognise urgent immunotherapy complications

Read emergency warning signs and immediate actions →